<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AZITHROMYCIN" rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol-lowering medication or another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the atorvastatin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20 mg/day of atorvastatin. If the therapeutic objective is not attained with this dosage, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the metabolism of the cholesterol-lowering medication)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 10mg/day of atorvastatin. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Administer weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol-lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use weaker doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="">
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPRVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the therapy with the two drug combination</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the hypokaliemiant, with risk of undesirable effects, especially muscular ones</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol lowering agent</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
</INTERACTIONS>
